In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said.
Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s proactive approach to chronic COVID-19 conditions, technology that can help diagnose new cases, and the likelihood that particular devices and components will be in greater demand in the years ahead.
Get the full story at our sister site, Medical Design & Outsourcing.
Dexcom VP of Global Clinical Initiatives Tomas Walker [Photo courtesy of Dexcom]
New data is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure.In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said.
Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s proactive approach to chronic COVID-19 conditions, technology that can help diagnose new cases, and the likelihood that particular devices and components will be in greater demand in the years ahead.
The following has been lightly edited for space and clarity.
MDO: How does the SARS-CoV-2 virus and its COVID-19 disease affect the pancreas?
Walker: In February, March of 2020, there were a couple of papers published out of China very early in the expe…
BTIG hosted a conference call with North Shore Medical Center (Salem, Massachusetts) Medical Director Dr. Gary Cohen and Healthcare Analytics, LLC analyst and consultant Dr. Joshua Cohen, with the two experts offering insight into prescriber and patient interest in continuous glucose monitors (CGMs) among type 2 diabetes non-intensive insulin therapy (T2 NIIT) patients.
Get the full story at our sister site, Drug Delivery Business News.
Kaiser Permanente touts a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes.
Patients with insulin-treated type 2 diabetes using continuous glucose monitors (CGMs) typically had better blood sugar control and fewer visits to the emergency room for hypoglycemia, the study found. The study was published yesterday in JAMA and was supported by an independent investigator award from Dexcom and funding from the National Institute of Diabetes and Digestive and Kidney Diseases.
Get the full story at our sister site, Drug Delivery Business News.
Kenyan long-distance runner Eliud Kipchoge is using a glucose sensor modeled after Abbott Laboratories’ FreeStyle Libre glucose monitor to optimize his training regimen.
The sensor, known as the Libre Sense Glucose Sport Biosensor, is the first device intended to help athletes track blood sugar rather than people with diabetes.
Get the full story from our sister site, Drug Delivery Business.
The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control.
Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.
Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.
Elkhart, Ind.–based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer. The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.
In the 1970s, Ames developed a device known as the Ames Reflectance Meter to m…
The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control.
Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.
Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.
Elkhart, Ind.–based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer. The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.
In the 1970s, Ames developed a device known as the Ames Reflectance Meter to m…
Continuous glucose monitors (CGMs) are among the most potent diabetes management tools to emerge in recent decades.
FDA approved the first professional CGM in 1999, and the technology has evolved swiftly since then. Current models beam data via Bluetooth to smartphones (plus the Apple Watch) and the cloud, enabling patients to explore their blood glucose readings in an app or via downloadable PDFs.
“Decades ago, we were still checking urine sugars,” said Dr. Egils Bogdanovics, a Connecticut-based endocrinologist. “In the early 1980s, fingerstick blood glucose monitors came out. That was a big deal — a revolution in diabetes,” Bogdanovics recalled.
Get the full story from our sister site, Drug Delivery Business.
Dexcom G6 sensor and applicator [Image from Dexcom]Continuous glucose monitors (CGMs) are among the most potent diabetes management tools to emerge in recent decades.
FDA approved the first professional CGM in 1999, and the technology has evolved swiftly since then. Current models beam data via Bluetooth to smartphones (plus the Apple Watch) and the cloud, enabling patients to explore their blood glucose readings in an app or via downloadable PDFs.
“Decades ago, we were still checking urine sugars,” said Dr. Egils Bogdanovics, a Connecticut-based endocrinologist. “In the early 1980s, fingerstick blood glucose monitors came out. That was a big deal — a revolution in diabetes,” Bogdanovics recalled.
But the fingerstick blood glucose monitor provides more of a snapshot than a moving picture. “About 15 years ago, professional continuous glucose monitoring was introduced. Initially, it was just endocrinologists [who used it], and we used it in what we called …